Pharmacodynamic markers and clinical results from the phase 2 study of the SMAC mimetic birinapant in women with relapsed platinum-resistant or -refractory epithelial ovarian cancer-Reference-Cited by-同舟云学术

Pharmacodynamic markers and clinical results from the phase 2 study of the SMAC mimetic birinapant in women with relapsed platinum-resistant or -refractory epithelial ovarian cancer

Published:2015-11-13 Issue:4 Volume:122 Page:588-597
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Noonan Anne M.¹,Bunch Kristen P.¹²,Chen Jin-Qiu³,Herrmann Michelle A.³,Lee Jung-Min¹,Kohn Elise C.¹,O'Sullivan Ciara C.¹,Jordan Elizabeth¹,Houston Nicole¹,Takebe Naoko⁴,Kinders Robert J.⁵,Cao Liang⁶,Peer Cody J.⁷,Figg W. Douglas⁷,Annunziata Christina M.¹

Affiliation:

1. Women's Malignancies Branch; National Cancer Institute; Bethesda Maryland

2. Department of Gynecologic Oncology; Walter Reed National Military Medical Center; Bethesda Maryland

3. Collaborative Protein Technology Resource; National Cancer Institute; Bethesda Maryland

4. Cancer Therapy Evaluation Program; National Cancer Institute; Shady Grove Maryland

5. Pharmacodynamic Assay Development and Implementation Section, Division of Cancer Treatment and Diagnosis; National Cancer Institute; Frederick Maryland

6. Cancer Genetics Branch; National Cancer Institute; Bethesda Maryland

7. Clinical Pharmacology Program, Office of the Clinical Director, Center for Cancer Research; National Cancer Institute; Bethesda Maryland

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference35 articles.

1. Apaf-1 oligomerizes into biologically active approximately 700-kDa and inactive approximately 1.4-MDa apoptosome complexes;Cain;J Biol Chem.,2000

2. Dysfunctional apoptosome activation in ovarian cancer: implications for chemoresistance;Liu;Cancer Res.,2002

3. Altered death receptor signaling promotes epithelial-to-mesenchymal transition and acquired chemoresistance;Antoon;Sci Rep.,2012

4. IAP family proteins-suppressors of apoptosis;Deveraux;Genes Dev.,1999

Cited by 74 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chimeric antigen receptor dendritic cells targeted delivery of a single tumoricidal factor for cancer immunotherapy;Cancer Immunology, Immunotherapy;2024-08-06

2. Ubiquitination and deubiquitination in cancer: from mechanisms to novel therapeutic approaches;Molecular Cancer;2024-07-25

3. Birinapant Reshapes the Tumor Immunopeptidome and Enhances Antigen Presentation;International Journal of Molecular Sciences;2024-03-25

4. Prognostic value and therapeutic potential of IAP family in head and neck squamous cell carcinoma;Aging;2024-02-15

5. Birinapant selectively enhances immunotoxin‐mediated killing of cancer cells conditional on the IAP protein levels within target cells;The FASEB Journal;2023-11-16